ABCL
Price
$11.80
Change
-$0.88 (-6.94%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
4.51B
24 days until earnings call
Intraday BUY SELL Signals
CADL
Price
$8.20
Change
-$0.71 (-7.97%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
856.24M
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs CADL

ABCL vs CADL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABCL vs. CADL commentary
Oct 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and CADL is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABCL with price predictions
Oct 15, 2026

ABCL's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for ABCL moved out of overbought territory on October 01, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 instances where the indicator moved out of the overbought zone. In 26 of the 30 cases the stock moved lower in the days that followed. This puts the odds of a move down at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABCL as a result. In 73 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 36 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

ABCL broke above its upper Bollinger Band on September 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 204 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 135 of 165 cases where ABCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.035) is normal, around the industry mean (26.782). P/E Ratio (11.976) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (437.542).

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for CADL with price predictions
Oct 15, 2026

CADL in downward trend: price dove below 50-day moving average on September 25, 2026

CADL moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CADL as a result. In 84 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The 10-day moving average for CADL crossed bearishly below the 50-day moving average on September 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CADL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for CADL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in 212 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

CADL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.789) is normal, around the industry mean (26.782). P/E Ratio (46.083) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).

The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
ABCL: Fundamental Ratings
ABCL
OUTLOOK RATING
1..100
76
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
71
SEASONALITY SCORE
1..100
10

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLCADL
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 12 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
COMPARISON
Comparison
Oct 16, 2026
Stock price -- (ABCL: $12.68 vs. CADL: $8.91)
Brand notoriety: ABCL and CADL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 84% vs. CADL: 84%
Market capitalization -- ABCL: $4.51B vs. CADL: $856.24M
ABCL [@Biotechnology] is valued at $4.51B. CADL’s [@Biotechnology] market capitalization is $856.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green while CADL’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • CADL’s FA Score: 0 green, 5 red.
According to our system of comparison, both ABCL and CADL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 3 TA indicator(s) are bullish while CADL’s TA Score has 4 bullish TA indicator(s).

  • ABCL’s TA Score: 3 bullish, 5 bearish.
  • CADL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CADL is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а +5.49% price change this week, while CADL (@Biotechnology) price change was -7.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.28%. For the same industry, the average monthly price growth was -17.87%, and the average quarterly price growth was -21.14%.

Reported Earning Dates

ABCL is expected to report earnings on Nov 09, 2026.

CADL is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-10.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABCL
Daily Signal:
Gain/Loss:
CADL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STE224.337.07
+3.25%
STERIS plc
FTH20.600.60
+3.00%
Faeth Therapeutics Inc
LION11.020.13
+1.19%
Lionsgate Studios Corp
DOYU3.58-0.05
-1.38%
DouYu International Holdings Limited
WVVI2.00-0.10
-4.76%
Willamette Valley Vineyards

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+2.51%
RXRX - ABCL
58%
Loosely correlated
+11.23%
ABSI - ABCL
56%
Loosely correlated
+1.60%
VCYT - ABCL
56%
Loosely correlated
+2.02%
CRSP - ABCL
55%
Loosely correlated
+2.59%
AXON - ABCL
51%
Loosely correlated
+2.15%
More

CADL and

Correlation & Price change

A.I.dvisor indicates that over the last year, CADL has been loosely correlated with EDIT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CADL jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CADL
1D Price
Change %
CADL100%
-1.76%
EDIT - CADL
46%
Loosely correlated
+7.49%
CRSP - CADL
44%
Loosely correlated
+2.59%
BEAM - CADL
43%
Loosely correlated
+4.57%
SANA - CADL
42%
Loosely correlated
+6.22%
ABSI - CADL
42%
Loosely correlated
+1.60%
More